Emetine


Concise Prescribing Info
Indications/Uses
Severe invasive amoebiasis.
Dosage/Direction for Use
Adult : IM/SC Refer to product information for full dosing guidelines.
Dosage Details
Parenteral
Severe invasive amoebiasis
Adult: Dose may be given via IM or SC inj. For full dosing guidelines, refer to product information.
Contraindications
Cardiac, renal or neuromuscular disease. Avoid use in pregnancy.
Special Precautions
Avoid contact with mucous membranes as it is an irritant. Close supervision and ECG monitoring is recommended during treatment. Children, elderly and debilitated patients. Avoid chronic use as drug accumulation may lead to potentially fatal toxicity.
Adverse Reactions
Muscle ache, tenderness, stiffness and weakness at the Inj site; necrosis and abscess formation. Diarrhoea, nausea and vomiting; dizziness and headache. Rarely, mild sensory disturbances; eczematous, urticarial and purpuric skin lesions. CV effects, changes in the ECG particularly flattening or invasion of the T-wave and prolongation of the QT interval. Lesions of the heart, GIT, kidneys, liver and skeletal muscle with large doses or prolonged administration.
Potentially Fatal: Severe acute degenerative myocarditis which may give rise to sudden cardiac failure and death.
Action
Description: Emetine, an alkaloid of ipecac and a tissue amoebicide acts principally in the bowel wall and in the liver. It is used in the treatment of severe invasive amoebiasis.
Pharmacokinetics:
Distribution: After inj, emetine is concentrated mainly in the liver and to a certain degree, it is also found in the kidneys, lungs and spleen.
Excretion: Slow excretion and amounts may still be detected in the urine 40-60 days after treatment has stopped.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Emetine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in